Clinical trials: Advanced Malignant Tumor
Advanced Cutaneous Melanoma
ITIL-168 in Advanced Melanoma
DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor.
- Trial name
- DELTA-1 (NCT05050006)
- Testing
- ITIL-168
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Instil Bio
Solid Tumor, C-Met Mutation-Related Tumors
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple…
- Trial name
- NCT04228406
- Testing
- GST-HG161
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Advanced Solid Malignancies
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ceralasertib in Japanese patients with advanced solid malignancies.
- Trial name
- NCT05469919
- Testing
- Ceralasertib
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Malignant Ascites, Gastrointestinal Cancers
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Malignant ascites represents a severe clinical problem for physicians and patients being confronted with this common symptom of advanced-stage gastrointestinal cancer.
- Trial name
- NCT01200121
- Testing
- Bevacizumab
- Where
- 26 sites in Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Solid Tumor
Phase I Study of SHR7390 in Patients With Advanced Solid Tumors
This aim of study to assess the safety and tolerability of SHR7390 and to define the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.
- Trial name
- NCT02968485
- Testing
- SHR7390
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.
- Trial name
- NCT06144671
- Testing
- GT201, IL-2, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Grit Biotechnology
Advanced Solid Tumor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal…
- Trial name
- NCT05824663
- Testing
- HBM1020
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Harbour BioMed US, Inc.
Osteosarcoma, Neuroblastoma
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
Cd276 (B7-H3) is an ideal target for car-t treatment because of its high expression on the surface of neuroblastoma, osteosarcoma, gastric cancer and lung cancer cells, but not in normal peripheral cells or tissues.
- Conditions
- Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT04864821
- Testing
- Targeting CD276 CAR T cells
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Advanced Intrahepatic Cholangiocarcinoma
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
The main purpose of this study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody and standard chemotherapy regimen for the treatment of…
- Trial name
- NCT06956716
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + cisplatin (GP), Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Rectal Cancer
Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells
During the course of tumor growth and possibly by manipulation during the surgical procedure, cells from rectal tumors may be shed into the peritoneal cavity.
- Trial name
- LARC-EX (NCT02113384)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 231 people
- Sponsor
- Oslo University Hospital
Breast Cancer, Metastatic Breast Cancer
Trastuzumab and Vinorelbine in Advanced Breast Cancer
The purpose of this research study is to see what effects trastuzumab in combination with vinorelbine has on breast cancer when the participant has circulating tumor cells that are positive for the protein called HER2.
- Trial name
- NCT01185509
- Testing
- trastuzumab, vinorelbine
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Tumor
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in…
- Trial name
- NCT06823609
- Testing
- QLS1304 tablet
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Solid Tumor, Advanced Cancer
High Definition Medicine for Solid Tumors Oncology
The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their…
- Trial name
- HDM-PMP22 (NCT06590506)
- Testing
- Wearable
- Where
- 9 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Advanced Solid Tumors
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
The therapeutic approach taken by trial SAKK 66/17 is different from those already used in clinical practice and possibly offers patients a therapeutic benefit after failure of standard chemotherapy and immunotherapy.
- Trial name
- NCT03993678
- Testing
- IP-001, Thermal Ablation
- Where
- 3 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Swiss Cancer Institute
Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer
This clinical trial examines a web-based tool, in partnership with Peacefully, Inc, designed to improve end-of-life planning among patients with advanced cancers.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05564468
- Testing
- Best Practice, Internet-Based Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor, Adult, Breast Cancer
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer
- Trial name
- NCT03149549
- Testing
- CX-2009
- Where
- 26 sites in United States, Netherlands and 2 more
- Volunteers
- 99 people
- Sponsor
- CytomX Therapeutics
Gastric Cancer
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
This trial is an investigator-initiated, single-center, open-label, single-arm exploratory study of mRNA neoantigen tumor vaccine in the treatment of advanced gastric cancer, including two phases: dose escalation and dose…
- Trial name
- NCT05227378
- Testing
- neoantigen tumor vaccine with or without PD-1/L1
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shen Lin
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.